EP2723354A4 - Compositions, utilisations et préparation de lysats de plaquettes - Google Patents
Compositions, utilisations et préparation de lysats de plaquettesInfo
- Publication number
- EP2723354A4 EP2723354A4 EP12804449.2A EP12804449A EP2723354A4 EP 2723354 A4 EP2723354 A4 EP 2723354A4 EP 12804449 A EP12804449 A EP 12804449A EP 2723354 A4 EP2723354 A4 EP 2723354A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- preparation
- platelet lysates
- lysates
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0666—Mesenchymal stem cells from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161501411P | 2011-06-27 | 2011-06-27 | |
US201161547897P | 2011-10-17 | 2011-10-17 | |
PCT/US2012/044211 WO2013003356A1 (fr) | 2011-06-27 | 2012-06-26 | Compositions, utilisations et préparation de lysats de plaquettes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20176185.5 Division-Into | 2020-05-22 |
Publications (4)
Publication Number | Publication Date |
---|---|
EP2723354A1 EP2723354A1 (fr) | 2014-04-30 |
EP2723354A4 true EP2723354A4 (fr) | 2015-03-11 |
EP2723354B1 EP2723354B1 (fr) | 2020-05-27 |
EP2723354B3 EP2723354B3 (fr) | 2021-03-24 |
Family
ID=47424507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12804449.2A Active EP2723354B3 (fr) | 2011-06-27 | 2012-06-26 | Compositions, utilisations et préparation de lysats de plaquettes |
Country Status (8)
Country | Link |
---|---|
US (2) | US9688959B2 (fr) |
EP (1) | EP2723354B3 (fr) |
JP (1) | JP6179955B2 (fr) |
CN (2) | CN103702674B (fr) |
AU (1) | AU2012275562B2 (fr) |
CA (1) | CA2840568C (fr) |
ES (1) | ES2811085T7 (fr) |
WO (1) | WO2013003356A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9682104B2 (en) | 2012-01-26 | 2017-06-20 | Jadi Cell Llc | Lyophilized platelet lysates |
US20160002598A1 (en) * | 2013-01-28 | 2016-01-07 | Regenerative Science, LLC | Device and methods for platelet lysis or activation |
US10905721B2 (en) | 2013-01-28 | 2021-02-02 | Regenexx, Llc. | Device and methods for platelet lysis or activation |
CA2922205C (fr) | 2013-08-27 | 2021-08-17 | Cook General Biotechnology Llc | Compositions bioactives pouvant etre derivees de concentres de plaquettes, et procedes de preparation et d'utilisation de celles-ci |
HK1194912A2 (en) * | 2013-09-17 | 2014-10-24 | Bestop Group Holdings Ltd | Growth factor concentrate and the use thereof |
AU2015236088A1 (en) * | 2014-03-25 | 2016-11-10 | Cook Biotech Incorporated | Extracellular matrix grafts loaded with exogenous factors |
WO2016116560A1 (fr) * | 2015-01-21 | 2016-07-28 | Turkof Edvin | Concentré de plaquettes pour l'augmentation de la régénération de cellules et la croissance de cellules |
WO2016132357A1 (fr) * | 2015-02-16 | 2016-08-25 | Nayacure Therapeutics Ltd. | Caillots modifiés |
CA2987872A1 (fr) * | 2015-05-29 | 2016-12-08 | Amit Patel | Compositions de lysat de plaquettes lyophilisees particulaires |
CN107304412A (zh) * | 2016-04-22 | 2017-10-31 | 南京医科大学第附属医院 | 视网膜色素上皮细胞的培养基及其应用 |
EP3254684B1 (fr) | 2016-06-08 | 2019-10-23 | Lysatpharma GmbH | Lysat de plaquettes humaines ou fraction enrichie de vésicules extracellulaires dérivées de lysat de plaquettes humaines pour utilisation medicale |
WO2018005751A1 (fr) * | 2016-06-29 | 2018-01-04 | Arteriocyte, Inc. | Pansements composés d'un lysat de plaquettes. |
EP3558411B1 (fr) * | 2016-12-22 | 2024-04-17 | Regenexx, LLC | Dispositif et procédés de lyse ou d'activation plaquettaire |
IT201700026465A1 (it) * | 2017-03-09 | 2018-09-09 | Biorigen S R L | Supplementi per colture cellulari |
EP3638263B1 (fr) | 2017-06-16 | 2023-08-23 | Centre Hospitalier Régional et Universitaire de Lille (CHRU) | Procédé de préparation d'un lysat de plaquettes humaines regroupées en pool et leur utilisation pour le traitement de troubles neurologiques |
KR20200104300A (ko) * | 2017-12-22 | 2020-09-03 | 키에시 파르마슈티시 엣스. 피. 에이. | 중간엽 기질세포 및 탯줄로부터 중간엽 기질세포를 얻기 위한 방법 |
FR3077824B1 (fr) | 2018-02-15 | 2022-01-14 | Maco Pharma Sa | Procede de preparation d'un lysat plaquettaire irradie |
FR3077823B1 (fr) | 2018-02-15 | 2022-01-14 | Maco Pharma Sa | Procede de preparation d'un lysat plaquettaire irradie |
CN108823156A (zh) * | 2018-07-04 | 2018-11-16 | 陕西神州生物技术有限公司 | 用于修复的临床级人脐带间充质干细胞复合因子及冻干粉的制备方法 |
CN112912101A (zh) * | 2018-08-07 | 2021-06-04 | 爱菲斯医疗有限公司 | 血小板裂解物组合物及其用途 |
JP7416786B2 (ja) * | 2018-11-14 | 2024-01-17 | オンデルゾークス・エン オントビッケリングスフォンズ オーデ クラウス・フランデレン | 血小板放出物を調製するための方法 |
EP3886879A4 (fr) | 2018-11-30 | 2022-12-07 | Cellphire Inc. | Plaquettes en tant qu'agents de livraison |
EP3887404A4 (fr) | 2018-11-30 | 2022-11-02 | Cellphire, Inc. | Plaquettes chargées d'agents anticancéreux |
EP3920944A4 (fr) * | 2019-02-07 | 2023-03-29 | Biobridge Global | Méthodes et compositions associées à un produit de libération de plaquettes et à la fibrine riche en plaquettes |
SG11202112054WA (en) | 2019-05-03 | 2021-11-29 | Cellphire Inc | Materials and methods for producing blood products |
AU2020277774A1 (en) * | 2019-05-22 | 2021-12-09 | Thankstem S.R.L. | Method for expanding adult stem cells from whole blood |
BR112022002892A2 (pt) | 2019-08-16 | 2022-05-24 | Cellphire Inc | Trombossomos como um agente de reversão de agente antiplaqueta |
CA3152224A1 (fr) * | 2019-08-22 | 2021-02-25 | Abdalla S. AWIDI | Procede de preparation d'un lysat de plaquettes sans fibrine et utilisations dudit procede |
WO2021158622A1 (fr) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Plaquettes chargées antifibrinolytiques |
CN111303270B (zh) * | 2020-02-18 | 2022-04-01 | 浙江中医药大学 | 一种利用套装制备血小板生长因子浓集物的方法 |
EP3881858A1 (fr) | 2020-03-20 | 2021-09-22 | Rok Pangersic | Extrait de facteur de croissance dérivé de plaquettes traité à la chaleur destiné à être utilisé dans un procédé de prévention ou de traitement de défaut d'un tissu |
CN111569139A (zh) * | 2020-05-26 | 2020-08-25 | 上海市第六人民医院 | 一种负载血小板裂解液的自支撑自组装多层膜及其应用 |
EP4190892A1 (fr) * | 2020-07-31 | 2023-06-07 | Rainbow Inc. | Lysat de plaquettes dérivé de plaquettes autologues |
CN113667636A (zh) * | 2021-07-13 | 2021-11-19 | 安徽农业大学 | 猪血小板裂解液及其制备方法 |
CN114058576A (zh) * | 2021-11-22 | 2022-02-18 | 新乡医学院 | 一种血小板裂解液及其制备方法和应用 |
CN114317430A (zh) * | 2021-12-28 | 2022-04-12 | 河北银丰鼎诚生物技术有限公司 | 一种适用于脐血来源免疫细胞扩增的培养液 |
WO2023190736A1 (fr) * | 2022-03-29 | 2023-10-05 | 学校法人日本大学 | Procédé de production de cellules adipeuses dédifférenciées humaines et milieu de culture pour la production de cellules adipeuses dédifférenciées humaines à partir de cellules adipeuses matures humaines |
EP4276173A1 (fr) * | 2022-05-10 | 2023-11-15 | Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. | Composition stable de lysat de plaquettes humaines, procédés et utilisations de celle-ci |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198357A (en) * | 1988-04-26 | 1993-03-30 | Ellco Food Ab | Preparation of a blood platelet lysate for use in a cell culture medium for hybridoma cells |
US20090305401A1 (en) * | 2006-09-18 | 2009-12-10 | Dirk Strunk | Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics |
WO2010064267A1 (fr) * | 2008-12-05 | 2010-06-10 | Universita' Degli Studi Di Pavia | Lysat de plaquettes et compositions bioadhésives de celui-ci pour le traitement de la mucosite |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3366540D1 (en) * | 1982-04-28 | 1986-11-06 | Trustees Of The Garfield Westo | Processes for the production of blood products |
CZ20033097A3 (cs) | 2001-05-21 | 2004-06-16 | Omrix Biopharmaceuticals S.A. | Způsob odstranění plasmin(ogenu) z proteinových roztoků |
EP1798005B1 (fr) * | 2004-08-02 | 2009-09-09 | HONDA MOTOR CO., Ltd. | Procede de commande d'un robot mobile pourvu de jambes |
SE528214C2 (sv) * | 2005-06-23 | 2006-09-26 | Proliff Ab | Förfarande för framställning av blodplättslysat |
US7629158B2 (en) * | 2006-06-16 | 2009-12-08 | The Procter & Gamble Company | Cleaning and/or treatment compositions |
US7951593B2 (en) * | 2007-03-20 | 2011-05-31 | Universite Rene Descartes-Paris V | Culture medium for gingival fibroblasts |
WO2009085969A2 (fr) | 2007-12-19 | 2009-07-09 | Regenerative Sciences, Llc | Compositions et procédés pour favoriser l'implantation et la prise de greffe de cellules souches |
EP2077118A1 (fr) * | 2008-01-07 | 2009-07-08 | Gwo Rei Biomedical Technology Corp. | Concentré coagulo-actif de facteurs de croissance de plaquettes et son procédé de préparation |
EP2257176B1 (fr) | 2008-03-14 | 2013-09-18 | Regenerative Sciences, LLC | Compositions et procédés pour la réparation de cartilage |
WO2009155069A1 (fr) | 2008-05-28 | 2009-12-23 | Allan Mishra | Compositions et procédés pour traiter des troubles psychiatriques et neurodégénératifs |
WO2009152084A2 (fr) * | 2008-06-11 | 2009-12-17 | Cell4Vet Llc | Cellules souches dérivées d'un tissu adipeux à usage vétérinaire |
EP2334785B2 (fr) * | 2008-09-16 | 2019-08-14 | Mayo Foundation For Medical Education And Research | Compositions à contenu plaquettaire |
ES2438491T3 (es) | 2008-09-22 | 2014-01-17 | Omrix Biopharmaceuticals Ltd. | Dispositivo implantable que comprende un sustrato pre-recubierto con fibrina estabilizada |
ITPI20090066A1 (it) | 2009-05-26 | 2010-11-27 | Consiglio Nazionale Ricerche | Metodo per produrre un dispositivo applicabile a tessuti biologici, in particolare un patch per trattare tessuti danneggiati, e dispositivo ottenuto con tale metodo |
EP2389942B1 (fr) | 2010-05-25 | 2013-01-23 | GwoWei Technology Co., Ltd. | Lysat plaquettaire viralement inactivé contenant des facteurs de croissance et déplété en PDGF et VEGF et sa méthode de préparation |
EP2616550B1 (fr) | 2010-09-15 | 2016-02-10 | Debiopharm International SA | Procédé de séparation de molécules ou de particules cibles d'échantillons dont des composants sanguins contenant du fibrinogène |
IL210162A0 (en) * | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
EP2540819A1 (fr) | 2011-06-27 | 2013-01-02 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | Procédé de culture de cellules dans un milieu contenant un lysat de plaquettes |
EP2591812A1 (fr) | 2011-11-14 | 2013-05-15 | University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) | Petit tissu à base de dextrane contenant un lysat à plasma riche en plaquettes pour la réparation des cartilages |
US20140335195A1 (en) | 2011-11-23 | 2014-11-13 | Cell Therapy Limited | Platelet lysate gel |
US9682104B2 (en) | 2012-01-26 | 2017-06-20 | Jadi Cell Llc | Lyophilized platelet lysates |
WO2013116791A1 (fr) | 2012-02-02 | 2013-08-08 | Mosaic Biosciences, Inc. | Biomatériaux destinés à l'administration d'extraits sanguins et procédés les utilisant |
EP2733200A1 (fr) | 2012-11-15 | 2014-05-21 | Biorigen International SA | Suppléments de culture cellulaire |
CA2895652C (fr) | 2012-12-20 | 2020-10-27 | Omrix Biopharmaceuticals Ltd. | Melange biologique inactive viral |
CA2922205C (fr) * | 2013-08-27 | 2021-08-17 | Cook General Biotechnology Llc | Compositions bioactives pouvant etre derivees de concentres de plaquettes, et procedes de preparation et d'utilisation de celles-ci |
TW201914595A (zh) * | 2017-09-27 | 2019-04-16 | 法國里爾中央醫學中心 | 製備血小板裂解物組分的方法、血小板裂解物組分及其用於治療中樞神經系統疾病的用途 |
WO2019126494A1 (fr) * | 2017-12-20 | 2019-06-27 | Cook Regentec Llc | Compositions de plaquettes à teneur réduite en pathogènes et méthodes associées |
-
2012
- 2012-06-26 AU AU2012275562A patent/AU2012275562B2/en active Active
- 2012-06-26 CN CN201280036793.1A patent/CN103702674B/zh active Active
- 2012-06-26 US US14/129,448 patent/US9688959B2/en active Active
- 2012-06-26 EP EP12804449.2A patent/EP2723354B3/fr active Active
- 2012-06-26 WO PCT/US2012/044211 patent/WO2013003356A1/fr active Application Filing
- 2012-06-26 JP JP2014518918A patent/JP6179955B2/ja active Active
- 2012-06-26 CN CN201810498785.8A patent/CN108671224B/zh active Active
- 2012-06-26 CA CA2840568A patent/CA2840568C/fr active Active
- 2012-06-26 ES ES12804449T patent/ES2811085T7/es active Active
-
2017
- 2017-05-26 US US15/607,123 patent/US20170304365A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198357A (en) * | 1988-04-26 | 1993-03-30 | Ellco Food Ab | Preparation of a blood platelet lysate for use in a cell culture medium for hybridoma cells |
US20090305401A1 (en) * | 2006-09-18 | 2009-12-10 | Dirk Strunk | Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics |
WO2010064267A1 (fr) * | 2008-12-05 | 2010-06-10 | Universita' Degli Studi Di Pavia | Lysat de plaquettes et compositions bioadhésives de celui-ci pour le traitement de la mucosite |
Non-Patent Citations (4)
Title |
---|
DANIEL TZU-BI SHIH ET AL: "Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate", TRANSFUSION, vol. 51, no. 4, 1 April 2011 (2011-04-01), pages 770 - 778, XP055020793, ISSN: 0041-1132, DOI: 10.1111/j.1537-2995.2010.02915.x * |
ELIA RANZATO ET AL: "Platelet lysate promotes in vitro wound scratch closure of human dermal fibroblasts: different roles of cell calcium, P38, ERK and PI3K/AKT", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 13, no. 8b, 9 August 2008 (2008-08-09), pages 2030 - 2038, XP055140479, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2008.00467.x * |
See also references of WO2013003356A1 * |
WALTER GEREMICCA ET AL: "Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms", BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE, 1 April 2010 (2010-04-01), Italy, pages 107 - 112, XP055140470, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/20383304> DOI: 10.2450/2009.0091-09 * |
Also Published As
Publication number | Publication date |
---|---|
AU2012275562B2 (en) | 2016-10-20 |
EP2723354A1 (fr) | 2014-04-30 |
EP2723354B3 (fr) | 2021-03-24 |
ES2811085T3 (es) | 2021-03-10 |
CA2840568A1 (fr) | 2013-01-03 |
CA2840568C (fr) | 2021-05-04 |
US20170304365A1 (en) | 2017-10-26 |
AU2012275562A1 (en) | 2014-01-23 |
US9688959B2 (en) | 2017-06-27 |
CN103702674A (zh) | 2014-04-02 |
US20140127314A1 (en) | 2014-05-08 |
CN108671224B (zh) | 2022-12-13 |
EP2723354B1 (fr) | 2020-05-27 |
CN108671224A (zh) | 2018-10-19 |
CN103702674B (zh) | 2018-05-29 |
JP2014522833A (ja) | 2014-09-08 |
JP6179955B2 (ja) | 2017-08-16 |
WO2013003356A1 (fr) | 2013-01-03 |
ES2811085T7 (es) | 2021-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2723354A4 (fr) | Compositions, utilisations et préparation de lysats de plaquettes | |
HRP20180829T1 (hr) | Spojevi tioacetata, pripravci i postupci za uporabu | |
EP2785668A4 (fr) | Compositions ionisées fluides, leurs procédés de préparation et leurs utilisations | |
EP2582664A4 (fr) | Phénylthioacétates, compositions et procédés d'application | |
HK1207824A1 (en) | Polymorph compositions, methods of making, and uses thereof | |
EP2718331A4 (fr) | Polymères de n,n,n-trialkyle, procédés permettant leur élaboration, et utilisations de ceux-ci | |
ZA201404065B (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
EP2766375A4 (fr) | Préparation de nouveaux composés fluorés, procédés de préparation et compositions fabriquées à partir de ceux-ci | |
HK1198365A1 (en) | Imidazopyridine compounds, compositions and methods of use | |
EP2738159A4 (fr) | Composés de mercapto-benzophénone, compositions et procédés de préparation de ceux-ci | |
EP2766183A4 (fr) | Composition de fibre de fer, sa préparation et ses utilisations | |
HK1216891A1 (zh) | 苔蘚素組合物、其製備方法和用途 | |
EP2684869A4 (fr) | Préparation de 3-mercaptopropionates | |
EP2688576A4 (fr) | Extraits d'épiploon extraits à la chaleur, compositions, procédés de préparation et leurs utilisations | |
AU2011905060A0 (en) | Methods and Preparation and Uses of Xanthorrhoeaceae Compositions | |
AU2012905317A0 (en) | Methods and Preparation and Use of Xanthorrhoeaceae Compositions | |
PL392894A1 (pl) | Preparat o właściwościach prebiotycznych | |
PL392895A1 (pl) | Preparat o właściwościach prebiotycznych | |
IL232620B (en) | Tricyclic compounds, preparations including them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140106 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1195744 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150211 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 27/02 20060101ALI20150205BHEP Ipc: A61K 35/14 20150101AFI20150205BHEP Ipc: C12N 5/071 20100101ALI20150205BHEP Ipc: A61P 17/02 20060101ALI20150205BHEP Ipc: A61K 38/17 20060101ALI20150205BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190124 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20191125 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012070366 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1273827 Country of ref document: AT Kind code of ref document: T Effective date: 20200615 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200828 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200827 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200927 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200928 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200827 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1273827 Country of ref document: AT Kind code of ref document: T Effective date: 20200527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R055 Ref document number: 602012070366 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 |
|
PLCP | Request for limitation filed |
Free format text: ORIGINAL CODE: EPIDOSNLIM1 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLCQ | Request for limitation of patent found admissible |
Free format text: ORIGINAL CODE: 0009231 |
|
PLCR | Communication despatched that request for limitation of patent was allowed |
Free format text: ORIGINAL CODE: 0009245 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R056 Ref document number: 602012070366 Country of ref document: DE |
|
PLCN | Payment of fee for limitation of patent |
Free format text: ORIGINAL CODE: EPIDOSNRAL3 |
|
PUAM | (expected) publication of b3 document |
Free format text: ORIGINAL CODE: 0009410 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN LIMITED |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602012070366 Country of ref document: DE |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
LIM1 | Request for limitation found admissible |
Free format text: SEQUENCE NO: 1; FILED DURING OPPOSITION PERIOD Filing date: 20210126 Effective date: 20210126 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2811085 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210310 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200626 |
|
PLBP | Opposition withdrawn |
Free format text: ORIGINAL CODE: 0009264 |
|
26 | Opposition filed |
Opponent name: PILLER, FRANK Effective date: 20210226 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200630 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PLBD | Termination of opposition procedure: decision despatched |
Free format text: ORIGINAL CODE: EPIDOSNOPC1 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R100 Ref document number: 602012070366 Country of ref document: DE |
|
PLBM | Termination of opposition procedure: date of legal effect published |
Free format text: ORIGINAL CODE: 0009276 |
|
27C | Opposition proceedings terminated |
Effective date: 20220114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230601 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230510 Year of fee payment: 12 Ref country code: IE Payment date: 20230510 Year of fee payment: 12 Ref country code: FR Payment date: 20230510 Year of fee payment: 12 Ref country code: DE Payment date: 20230502 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230504 Year of fee payment: 12 Ref country code: ES Payment date: 20230711 Year of fee payment: 12 |